Skip to content

T +27 (0)21 900 6277
E reception@haemalife.co.za

A 4G Riverside View Chambers
Netcare Kuils River Hospital
33 Van Riebeeck Road
Kuils River
7580


Types of Conditions

THE CONTENT FOR THE VARIOUS CONDITIONS

AML
(Acute Myeloblastic Leukemia)

Is a cancer of the blood and bone marrow where the body makes a large number of abnormal myeloid white blood cells. These abnormal cells grow quickly, crowd out healthy blood cells, and interfere with normal blood function.
READ MORE

ALL
(Acute Lymphoblastic Leukemia)

Acute Lymphoblastic Leukemia (ALL) is a fast-growing cancer of the blood and bone marrow in which the body makes large numbers of immature white blood cells called lymphoblasts (usually B-cells, sometimes T-cells).
READ MORE

CLL
(Chronic Lymphocytic Leukemia)

Chronic Myeloid Leukemia (CML) is a slow-progressing cancer of the blood and bone marrow characterized by the overproduction of mature and immature myeloid white blood cells.
READ MORE

Myelomas
 

Myeloma (Multiple Myeloma) is a cancer of plasma cells, a type of white blood cell found in the bone marrow that normally produces antibodies.
READ MORE

Lymphomas
 

Lymphoma is a cancer of the lymphatic system that arises from lymphocytes (B cells, T cells, or NK cells), which are white blood cells involved in immune defense.
READ MORE

Bone Marrow Stem
Cell Transplants

The medical procedure in which damaged or diseased bone marrow is replaced with healthy stem cells to restore normal blood cell production.
READ MORE

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by

AML

Acute Myeloid Leukemia (AML) is a fast-growing cancer of the blood and bone marrow in which abnormal myeloid cells multiply and crowd out normal blood cells, leading to anemia, infections, and bleeding.

Diagnosis is made through blood tests showing abnormal cells, followed by a bone marrow biopsy. Additional tests such as cytogenetic, molecular, and immunophenotyping studies help confirm AML and guide treatment.

Types of AML are classified based on cell appearance and genetic changes. Major systems include the WHO and FAB classifications. Subtypes are defined by specific chromosome or gene abnormalities, such as acute promyelocytic leukemia (APL), which requires specialized therapy.

Treatment options depend on patient age, health, and AML subtype. They may include intensive chemotherapy, targeted therapies (such as FLT3 or IDH inhibitors), immunotherapy, and stem cell (bone marrow) transplantation. Supportive care, including antibiotics and blood transfusions, is also essential.

ALL

Acute Lymphoblastic Leukemia (ALL) is a fast-growing cancer of the blood and bone marrow in which immature lymphoid cells (B or T lymphocytes) multiply uncontrollably, crowding out normal blood cells and impairing immune function.

Diagnosis involves blood tests showing abnormal lymphoblasts, followed by a bone marrow biopsy. Immunophenotyping, cytogenetic, and molecular testing are used to confirm the diagnosis, classify the subtype, and assess prognosis.

Types of ALL are classified based on the lymphocyte involved (B-cell or T-cell ALL) and specific genetic abnormalities. Certain subtypes, such as Philadelphia chromosome–positive ALL, have important treatment implications.

Treatment options depend on age, risk factors, and genetic findings. Therapy typically includes multi-phase chemotherapy, targeted therapies (such as tyrosine kinase inhibitors), immunotherapy (including monoclonal antibodies or CAR T-cell therapy), and in some cases stem cell transplantation. Supportive care is essential throughout treatment.

CLL

Chronic Lymphocytic Leukemia (CLL) is a slow-growing cancer of B-lymphocytes, a type of white blood cell. In CLL, abnormal B-cells accumulate in the blood, bone marrow, and lymphoid tissues, often crowding out healthy cells and weakening the immune system.

Diagnosis is made through blood tests showing a high number of mature-looking lymphocytes, flow cytometry to confirm their identity, and sometimes bone marrow biopsy. Genetic testing helps predict disease course and guide treatment.

Types of CLL are classified mainly by genetic features (e.g., deletions of 17p, 13q, or mutations like TP53) and immunoglobulin heavy chain (IGHV) mutation status, which influence prognosis and therapy choice.

Treatment options depend on symptoms, disease progression, and risk factors. Many patients are initially monitored without treatment (“watch and wait”). When therapy is needed, options include targeted therapies (BTK inhibitors, BCL2 inhibitors), chemotherapy, monoclonal antibodies, and in select cases, stem cell transplantation. Supportive care focuses on managing infections and other complications.

MYELOMA

Multiple Myeloma (MM) is a cancer of plasma cells, a type of white blood cell that produces antibodies. In MM, abnormal plasma cells accumulate in the bone marrow, crowding out healthy cells and producing defective antibodies, which can cause organ damage.

Diagnosis involves blood tests (showing abnormal proteins or anemia), urine tests (detecting excess light chains), and a bone marrow biopsy. Imaging like X-rays, MRI, or PET/CT scans can detect bone lesions. Additional tests identify genetic changes that affect prognosis.

Types of Myeloma are often classified based on the type of abnormal protein produced (IgG, IgA, light-chain, etc.) and genetic features of the plasma cells. Smoldering (asymptomatic) myeloma is an early, slow-growing form.

Treatment options depend on age, health, and disease stage. Common approaches include chemotherapy, targeted therapies (like proteasome inhibitors or immunomodulators), immunotherapy (monoclonal antibodies), stem cell transplantation, and supportive care to manage bone disease, anemia, or kidney problems.

LYMPHOMA

Lymphomas are cancers of the lymphatic system, which includes lymph nodes, spleen, and other immune tissues. They arise when lymphocytes (B-cells or T-cells) grow uncontrollably, forming tumors and impairing normal immune function.

Diagnosis is made through physical examination of swollen lymph nodes, blood tests, imaging (CT, PET/CT), and a lymph node biopsy. Immunophenotyping and genetic tests help classify the lymphoma subtype and guide treatment.

Types of Lymphoma are broadly divided into:

  • Hodgkin Lymphoma (HL): Characterized by Reed-Sternberg cells; generally has a high cure rate.

  • Non-Hodgkin Lymphoma (NHL): Includes many subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) with variable aggressiveness.

Treatment options depend on lymphoma type, stage, and patient factors. They include chemotherapy, targeted therapies (like monoclonal antibodies), immunotherapy (including CAR T-cell therapy), radiation therapy, and stem cell transplantation. Supportive care manages symptoms and treatment side effects.

BONE MARROW TRANSPLANT

Bone Marrow Transplant (BMT) is a medical procedure in which damaged or diseased bone marrow is replaced with healthy stem cells, either from the patient (autologous) or a donor (allogeneic). It’s used to treat blood cancers (like leukemia, lymphoma, and myeloma) and some severe blood disorders.

Procedure and Timeline:

  1. Preparation (conditioning): High-dose chemotherapy ± radiation to destroy diseased marrow (about 1–2 weeks).
  2. Transplant: Infusion of healthy stem cells, similar to a blood transfusion (usually a few hours).
  3. Recovery (engraftment): Stem cells begin producing new blood cells over 2–4 weeks. Full immune recovery can take months to a year.

 

Positive Outcomes:

  • Can cure or significantly prolong remission in some blood cancers.
  • Restores healthy blood cell production, reducing risk of infection, anemia, and bleeding.
  • Enables delivery of high-dose chemotherapy that would otherwise be too toxic.

 

While powerful, it carries risks like infection, graft-versus-host disease (for allogeneic transplants), and complications from treatment, so it’s carefully managed by specialists.